Edition:
United States

Polyphor AG (POLN.S)

POLN.S on Swiss Exchange

21.95CHF
3:58am EST
Change (% chg)

CHF0.15 (+0.69%)
Prev Close
CHF21.80
Open
CHF21.95
Day's High
CHF21.95
Day's Low
CHF21.95
Volume
118
Avg. Vol
6,695
52-wk High
CHF40.00
52-wk Low
CHF20.00

Chart for

About

Polyphor AG is a Switzerland-based company, which is engaged in the development of novel antibiotics and other efficacious therapies. The Company's medicines pipeline includes Murepavadin (POL7080), a novel class of specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas infections; the Outer Membrane... (more)

Overall

No Ratios Available.

Financials

  POLN.S Industry Sector
P/E (TTM): -- 31.13 33.63
EPS (TTM): -- -- --
ROI: -- 15.55 15.02
ROE: -- 16.92 16.60

BRIEF-Polyphor Announces Positive Results From FDA Type B Guidance Meeting

* EQS-ADHOC: POLYPHOR ANNOUNCES POSITIVE RESULTS FROM THE FDA TYPE B GUIDANCE MEETING ON THE PLANNED PHASE III STUDY FOR BALIXAFORTIDE

Dec 03 2018

BRIEF-Polyphor: Protocol Agreement With FDA For Second Pivotal Phase III Study Of Murepavadin

* EQS-ADHOC: POLYPHOR ANNOUNCES PROTOCOL AGREEMENT WITH THE FDA FOR THE SECOND PIVOTAL PHASE III STUDY OF MUREPAVADIN

Oct 24 2018

BRIEF-Polyphor AG: CMDO Debra Barker To Leave Polyphor

* CHIEF MEDICAL AND DEVELOPMENT OFFICER DEBRA BARKER TO LEAVE POLYPHOR; FRANK WEBER TO ASSIST IN THE TRANSITION

Oct 24 2018

BRIEF-Polyphor H1 Total Loss At CHF 20.8 Mln

* OVERALL REVENUES INCREASED BY CHF 4.2 MILLION TO CHF 7.0 MILLION IN FIRST HALF OF 2018

Sep 06 2018

BRIEF-Polyphor: Novo Holdings Invests CHF 6.8 Million In Polyphor

* EQS-ADHOC: NOVO HOLDINGS INVESTS CHF 6.8 MILLION IN POLYPHOR TO ACCELERATE THE DEVELOPMENT OF NOVEL ANTIBIOTICS AGAINST MULTI-DRUG RESISTANT GRAM-NEGATIVE PATHOGENS

Sep 06 2018

BRIEF-Polyphor Announces Listing Of New Shares Related To Convertible Loan Facility Agreement

* ANNOUNCES LISTING OF NEW SHARES RELATED TO CONVERTIBLE LOAN FACILITY AGREEMENT WITH WELLCOME TRUST

Jul 17 2018

Earnings vs. Estimates